Literature DB >> 14705118

Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: Insights into the pathophysiology of acute stroke in the thrombolysis era.

Julio A Chalela1, Dong-Wha Kang, Marie Luby, Mustapha Ezzeddine, Lawrence L Latour, Jason W Todd, Billy Dunn, Steven Warach.   

Abstract

We measured ischemic brain changes with diffusion and perfusion MRI in 42 ischemic stroke patients before and 2 hours (range approximately 1.5 to 4.5 hours) after standard intravenous tissue plasminogen activator (tPA) therapy. The median time from stroke onset to tPA was 131 minutes. Clinical and MRI variables (change in perfusion and/or diffusion weighted lesion volume) were compared between those with excellent outcome defined as 3-month modified Rankin score (mRS) of 0 to 1 and those with incomplete recovery (mRS >1). In multivariate logististic regression analysis, the most powerful independent predictor for excellent outcome was improved brain perfusion: hypoperfusion volume on mean transit time (MTT) map decrease >30% from baseline to 2-hour post tPA scan (p=0.009; odds ratio [95% confidence interval], 20.7 [2.1-203.9]). Except for age < 70 years, no other baseline clinical or imaging variable was an independent predictor of outcome. We propose MTT lesion volume decrease more than 30% 2 hours after tPA as an early marker of long-term clinical benefit of thrombolytic therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14705118     DOI: 10.1002/ana.10781

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  30 in total

Review 1.  Applications of diffusion/perfusion magnetic resonance imaging in experimental and clinical aspects of stroke.

Authors:  Timothy Q Duong; Marc Fisher
Journal:  Curr Atheroscler Rep       Date:  2004-07       Impact factor: 5.113

2.  The Efficacy of IV Tissue Plasminogen Activator for Restoring Cerebral Blood Flow in the Hours Immediately after Administration in Patients with Acute Stroke.

Authors:  Shahram Majidi; Alexis N Simpkins; Richard Leigh
Journal:  J Neuroimaging       Date:  2018-12-03       Impact factor: 2.486

Review 3.  Neuroimaging of ischemia and infarction.

Authors:  Erica C Sá de Camargo; Walter J Koroshetz
Journal:  NeuroRx       Date:  2005-04

Review 4.  Foundations of advanced magnetic resonance imaging.

Authors:  Roland Bammer; Stefan Skare; Rexford Newbould; Chunlei Liu; Vincent Thijs; Stefan Ropele; David B Clayton; Gunnar Krueger; Michael E Moseley; Gary H Glover
Journal:  NeuroRx       Date:  2005-04

5.  Multimodal MR examination in acute ischemic stroke.

Authors:  D M Mezzapesa; M Petruzzellis; V Lucivero; M Prontera; A Tinelli; M Sancilio; A Carella; F Federico
Journal:  Neuroradiology       Date:  2006-03-01       Impact factor: 2.804

Review 6.  Hyperacute imaging of ischemic stroke: role in therapeutic management.

Authors:  Scott L Selco; David S Liebeskind
Journal:  Curr Cardiol Rep       Date:  2005-01       Impact factor: 2.931

7.  Reliability of MR perfusion-weighted and diffusion-weighted imaging mismatch measurement methods.

Authors:  M Luby; S Warach
Journal:  AJNR Am J Neuroradiol       Date:  2007-09-20       Impact factor: 3.825

8.  Reperfusion half-life: a novel pharmacodynamic measure of thrombolytic activity.

Authors:  José G Merino; Lawrence L Latour; Li An; Amie W Hsia; Dong-Wha Kang; Steven Warach
Journal:  Stroke       Date:  2008-05-01       Impact factor: 7.914

9.  Effects of intravenous dimethyl sulfoxide on ischemia evolution in a rat permanent occlusion model.

Authors:  Juergen Bardutzky; Xianjun Meng; James Bouley; Timothy Q Duong; Rajiv Ratan; Marc Fisher
Journal:  J Cereb Blood Flow Metab       Date:  2005-08       Impact factor: 6.200

10.  Prevalence of a Multiple Territory Stroke Pattern After Intravenous Thrombolysis.

Authors:  Muhammad Umer Azeem; Muhammad Nagy; Malgorzata M Miller; Mehdi Ghasemi; Abdul Mikati; Brian Silver; Majaz Moonis; Nils Henninger
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-02-21       Impact factor: 2.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.